Adamas Pharmaceuticals Inc (ADMS) Fundamental Analysis & Valuation

NASDAQ:ADMS

Current stock price

8.22
+0.06 (+0.74%)
At close:
8.3
+0.08 (+0.97%)
After Hours:

This ADMS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. ADMS Profitability Analysis

1.1 Basic Checks

  • ADMS had negative earnings in the past year.
ADMS Yearly Net Income VS EBIT VS OCF VS FCFADMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 -20M -40M -60M -80M -100M

1.2 Ratios

Industry RankSector Rank
ROA -43.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADMS Yearly ROA, ROE, ROICADMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 0 2K 4K 6K 8K 10K

1.3 Margins

Industry RankSector Rank
OM -44.55%
PM (TTM) -71.1%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ADMS Yearly Profit, Operating, Gross MarginsADMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. ADMS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ADMS has been increased compared to 1 year ago.
  • Compared to 1 year ago, ADMS has a worse debt to assets ratio.
ADMS Yearly Shares OutstandingADMS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 5M 10M 15M 20M 25M
ADMS Yearly Total Debt VS Total AssetsADMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 50M 100M 150M 200M

2.2 Solvency

  • ADMS has an Altman-Z score of -3.57. This is a bad value and indicates that ADMS is not financially healthy and even has some risk of bankruptcy.
  • A Debt/Equity ratio of -5.76 indicates that ADMS is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Altman-Z -3.57
ROIC/WACCN/A
WACCN/A
ADMS Yearly LT Debt VS Equity VS FCFADMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 0 50M -50M 100M -100M

2.3 Liquidity

  • ADMS has a Current Ratio of 4.53. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
  • ADMS has a Quick Ratio of 4.17. This indicates that ADMS is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 4.53
Quick Ratio 4.17
ADMS Yearly Current Assets VS Current LiabilitesADMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. ADMS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 46.84% over the past year.
  • ADMS shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.34%.
  • ADMS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 107.84% yearly.
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%

3.2 Future

  • The Earnings Per Share is expected to grow by 12.28% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 20.86% on average over the next years. This is a very strong growth
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMS Yearly Revenue VS EstimatesADMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADMS Yearly EPS VS EstimatesADMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

Find the best growth stocksShow best growing peers

1

4. ADMS Valuation Analysis

4.1 Price/Earnings Ratio

  • ADMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year ADMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADMS Price Earnings VS Forward Price EarningsADMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.88
ADMS Per share dataADMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

  • ADMS's earnings are expected to grow with 24.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.88%
EPS Next 3Y24.11%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ADMS Dividend Analysis

5.1 Amount

  • ADMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ADMS Fundamentals: All Metrics, Ratios and Statistics

Adamas Pharmaceuticals Inc

NASDAQ:ADMS (11/23/2021, 4:18:38 PM)

After market: 8.3 +0.08 (+0.97%)

8.22

+0.06 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A
Earnings (Next)03-01
Inst Owners0.22%
Inst Owner Change0%
Ins Owners4.9%
Ins Owner Change0%
Market Cap374.98M
Revenue(TTM)88.19M
Net Income(TTM)-62.70M
Analysts71.43
Price Target8.69 (5.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA -10.88
EPS(TTM)-2.02
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS1.93
BVpS-0.47
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -43.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM -44.55%
PM (TTM) -71.1%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity -5.76
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.53
Quick Ratio 4.17
Altman-Z -3.57
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.87%
EPS Next Y48.66%
EPS Next 2Y34.88%
EPS Next 3Y24.11%
EPS Next 5Y12.28%
Revenue 1Y (TTM)26.34%
Revenue growth 3Y407.4%
Revenue growth 5Y107.84%
Sales Q2Q%28.33%
Revenue Next Year26.58%
Revenue Next 2Y29.99%
Revenue Next 3Y21.96%
Revenue Next 5Y20.86%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Adamas Pharmaceuticals Inc / ADMS Fundamental Analysis FAQ

What is the fundamental rating for ADMS stock?

ChartMill assigns a fundamental rating of 4 / 10 to ADMS.


Can you provide the valuation status for Adamas Pharmaceuticals Inc?

ChartMill assigns a valuation rating of 0 / 10 to Adamas Pharmaceuticals Inc (ADMS). This can be considered as Overvalued.


How profitable is Adamas Pharmaceuticals Inc (ADMS) stock?

Adamas Pharmaceuticals Inc (ADMS) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for ADMS stock?

The Earnings per Share (EPS) of Adamas Pharmaceuticals Inc (ADMS) is expected to grow by 48.66% in the next year.